Cargando…
Author Correction: Development of a novel anti-hepatitis B virus agent via Sp1
Autores principales: | Hayakawa, Michiyo, Umeyama, Hideaki, Iwadate, Mitsuo, Taguchi, Y.-H., Yano, Yoshihiko, Honda, Takashi, Itami-Matsumoto, Saori, Kozuka, Ritsuzo, Enomoto, Masaru, Tamori, Akihiro, Kawada, Norifumi, Murakami, Yoshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171149/ https://www.ncbi.nlm.nih.gov/pubmed/32313085 http://dx.doi.org/10.1038/s41598-020-63866-z |
Ejemplares similares
-
Development of a novel anti-hepatitis B virus agent via Sp1
por: Hayakawa, Michiyo, et al.
Publicado: (2020) -
Circulating Exosomal miRNA Profiles Predict the Occurrence and Recurrence of Hepatocellular Carcinoma in Patients with Direct-Acting Antiviral-Induced Sustained Viral Response
por: Itami-Matsumoto, Saori, et al.
Publicado: (2019) -
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed
por: Nonomura, Ayami, et al.
Publicado: (2021) -
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed
por: Yoshida, Kanako, et al.
Publicado: (2017) -
Stagnation of histopathological improvement is a predictor of hepatocellular carcinoma development after hepatitis C virus eradication
por: Motoyama, Hiroyuki, et al.
Publicado: (2018)